180 related articles for article (PubMed ID: 21487235)
1. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3-4, 2011, Freiburg, Germany.
Reichert JM
MAbs; 2011; 3(3):223-40. PubMed ID: 21487235
[TBL] [Abstract][Full Text] [Related]
2. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
Reichert JM; Beck A; Iyer H
MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
[TBL] [Abstract][Full Text] [Related]
3. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
4. Regulatory considerations in oncologic biosimilar drug development.
Macdonald JC; Hartman H; Jacobs IA
MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
[TBL] [Abstract][Full Text] [Related]
5. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
6. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
Scott BJ; Klein AV; Wang J
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
[TBL] [Abstract][Full Text] [Related]
7. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
8. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
9. Overhauling oversight--European drug legislation.
Tsang L
Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
[TBL] [Abstract][Full Text] [Related]
11. Registration of similar biological products--Singapore's approach.
Poh J; Tam KT
Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
[TBL] [Abstract][Full Text] [Related]
12. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
Moorkens E; Vulto AG; Huys I
MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
[TBL] [Abstract][Full Text] [Related]
13. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
14. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry.
Beck A; Reichert JM
MAbs; 2013; 5(5):621-3. PubMed ID: 23924791
[TBL] [Abstract][Full Text] [Related]
15. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar and interchangable biologic medications.
Simonson W
Geriatr Nurs; 2016; 37(5):393-394. PubMed ID: 27637457
[No Abstract] [Full Text] [Related]
17. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
Calvo B; Zuñiga L
Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
[TBL] [Abstract][Full Text] [Related]
18. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
20. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
Cook G; France G; Holte Ø; Lorenti G; Tainsh D
PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]